Bacillus mesentericus TO-A

Bacillus mesentericus TO-A is a specific strain of Gram-positive, spore-forming bacteria widely utilized as a probiotic agent for the management of gastrointestinal disturbances. Unlike traditional therapeutic targets such as individual human receptors or enzymes, this organism acts as a live biotherapeutic that modifies the host's microbiome and intestinal ecosystem. It is most commonly administered in symbiotic formulations, such as the Bio-Three preparation, where it works in tandem with other beneficial strains like Clostridium butyricum and Enterococcus faecalis. The strain facilitates the growth of indigenous beneficial bacteria by secreting essential enzymes and unique growth factors like 3,3-dihydroxyazetidine, which help maintain a healthy gut pH and microflora balance. In clinical settings, it is primarily indicated for treating diarrhea, constipation, and irritable bowel syndrome, as well as for restoring gut flora following antibiotic treatment. Its therapeutic profile is characterized by its ability to competitively inhibit pathogens and modulate the local immune response within the gastrointestinal tract.

Other names

Bacillus mesentericus strain TO-ABacillus mesentericus TO-A JPCB. mesentericus TO-A

Bacillus mesentericus TO-A functions as a symbiotic probiotic that modulates the intestinal environment. It secretes growth-promoting metabolites, specifically 3,3-dihydroxyazetidine (BM-1), which significantly enhances the proliferation of beneficial Bifidobacterium and Clostridium butyricum species. Additionally, it produces digestive enzymes like amylase and protease that assist in nutrient breakdown and the creation of prebiotic substrates. These actions restore microbial balance, strengthen the intestinal barrier, and inhibit the colonization of pathogens through competitive exclusion and immunomodulation, such as increasing secretory IgA levels.